APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Gene Therapy

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Selected research

Market Analysis & Forecast

Global Hemophilia Gene Therapy Market Analysis and Forecast 2026-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchHemophilia Gene Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Gene Therapy Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Hemophilia Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Gene Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Gene Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.

Report Includes

Read the full market overview

This report presents an overview of global market for Hemophilia Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemophilia Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemophilia Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemophilia Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hemophilia Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Hemophilia Gene Therapy Segment by Company

Spark Therapeutics

Ultragenyx

Shire PLC

Sangamo Therapeutics

Bioverativ

BioMarin

uniQure

Freeline Therapeutics

Hemophilia Gene Therapy Segment by Type

Hemophilia A

Hemophilia B

Hemophilia Gene Therapy Segment by Application

Hemophilia A Gene Therapy

Hemophilia B Gene Therapy

Hemophilia Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hemophilia Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hemophilia Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemophilia Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hemophilia A Major Player Table 3. Hemophilia B Major Player Table 4. Global Hemophilia Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hemophilia A Gene Therapy Major Player Table 6. Hemophilia B Gene Therapy Major Player Table 7. Hemophilia Gene Therapy Industry Trends Table 8. Hemophilia Gene Therapy Industry Drivers Table 9. Hemophilia Gene Therapy Industry Opportunities and Challenges Table 10. Hemophilia Gene Therapy Industry Restraints Table 11. Global Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Hemophilia Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Hemophilia Gene Therapy Market Share by Region (2021-2026) Table 14. Global Hemophilia Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Hemophilia Gene Therapy Market Share by Region (2027-2032) Table 16. Global Hemophilia Gene Therapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Hemophilia Gene Therapy Revenue Market Share by Players (2021-2026) Table 18. Global Hemophilia Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Hemophilia Gene Therapy Key Players Headquarters & Area Served Table 20. Global Hemophilia Gene Therapy Players, Product Type & Application Table 21. Global Hemophilia Gene Therapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Hemophilia Gene Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Hemophilia Gene Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Hemophilia Gene Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Hemophilia Gene Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Hemophilia Gene Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Hemophilia Gene Therapy Revenue Market Share by Application (2027-2032) Table 34. Spark Therapeutics Company Information Table 35. Spark Therapeutics Business Overview Table 36. Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Spark Therapeutics Hemophilia Gene Therapy Product Portfolio Table 38. Spark Therapeutics Recent Development Table 39. Ultragenyx Company Information Table 40. Ultragenyx Business Overview Table 41. Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Ultragenyx Hemophilia Gene Therapy Product Portfolio Table 43. Ultragenyx Recent Development Table 44. Shire PLC Company Information Table 45. Shire PLC Business Overview Table 46. Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Shire PLC Hemophilia Gene Therapy Product Portfolio Table 48. Shire PLC Recent Development Table 49. Sangamo Therapeutics Company Information Table 50. Sangamo Therapeutics Business Overview Table 51. Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio Table 53. Sangamo Therapeutics Recent Development Table 54. Bioverativ Company Information Table 55. Bioverativ Business Overview Table 56. Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bioverativ Hemophilia Gene Therapy Product Portfolio Table 58. Bioverativ Recent Development Table 59. BioMarin Company Information Table 60. BioMarin Business Overview Table 61. BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. BioMarin Hemophilia Gene Therapy Product Portfolio Table 63. BioMarin Recent Development Table 64. uniQure Company Information Table 65. uniQure Business Overview Table 66. uniQure Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. uniQure Hemophilia Gene Therapy Product Portfolio Table 68. uniQure Recent Development Table 69. Freeline Therapeutics Company Information Table 70. Freeline Therapeutics Business Overview Table 71. Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio Table 73. Freeline Therapeutics Recent Development Table 74. North America Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 75. North America Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 76. North America Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 77. North America Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 78. North America Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Hemophilia Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 80. North America Hemophilia Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 81. Europe Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 82. Europe Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 83. Europe Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 84. Europe Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 85. Europe Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Hemophilia Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 87. Europe Hemophilia Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 88. China Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 89. China Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 90. China Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 91. China Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 92. Asia Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 93. Asia Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 94. Asia Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 95. Asia Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Hemophilia Gene Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Hemophilia Gene Therapy Revenue by Region (US$ Million) & (2021-2026) Table 98. Asia Hemophilia Gene Therapy Revenue by Region (US$ Million) & (2027-2032) Table 99. SAMEA Hemophilia Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 100. SAMEA Hemophilia Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 101. SAMEA Hemophilia Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 102. SAMEA Hemophilia Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 103. SAMEA Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. SAMEA Hemophilia Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 105. SAMEA Hemophilia Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Hemophilia Gene Therapy Image Figure 2. Global Hemophilia Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hemophilia A Image Figure 5. Hemophilia B Image Figure 6. Global Hemophilia Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hemophilia Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hemophilia A Gene Therapy Image Figure 9. Hemophilia B Gene Therapy Image Figure 10. Global Hemophilia Gene Therapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Hemophilia Gene Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hemophilia Gene Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Hemophilia Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Hemophilia Gene Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hemophilia Gene Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Hemophilia Gene Therapy Revenue Market Share by Type (2021-2032) Figure 18. Global Hemophilia Gene Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America Hemophilia Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Hemophilia Gene Therapy Revenue Share by Type (2021-2032) Figure 23. North America Hemophilia Gene Therapy Revenue Share by Application (2021-2032) Figure 24. North America Hemophilia Gene Therapy Revenue Share by Country (2021-2032) Figure 25. United States Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Hemophilia Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Hemophilia Gene Therapy Revenue Share by Type (2021-2032) Figure 30. Europe Hemophilia Gene Therapy Revenue Share by Application (2021-2032) Figure 31. Europe Hemophilia Gene Therapy Revenue Share by Country (2021-2032) Figure 32. Germany Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Hemophilia Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Hemophilia Gene Therapy Revenue Share by Type (2021-2032) Figure 42. China Hemophilia Gene Therapy Revenue Share by Application (2021-2032) Figure 43. Asia Hemophilia Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Hemophilia Gene Therapy Revenue Share by Type (2021-2032) Figure 45. Asia Hemophilia Gene Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Hemophilia Gene Therapy Revenue Share by Region (2021-2032) Figure 47. Japan Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Hemophilia Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Hemophilia Gene Therapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Hemophilia Gene Therapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Hemophilia Gene Therapy Revenue Share by Country (2021-2032) Figure 57. Brazil Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Hemophilia Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Hemophilia A
  • Hemophilia B
Applications
  • Hemophilia A Gene Therapy
  • Hemophilia B Gene Therapy
Companies covered
  • Spark Therapeutics
  • Ultragenyx
  • Shire PLC
  • Sangamo Therapeutics
  • Bioverativ
  • BioMarin
  • uniQure
  • Freeline Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemophilia Gene Therapy Market by Type
  3. 1.2.1 Global Hemophilia Gene Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hemophilia A
  5. 1.2.3 Hemophilia B
  6. 1.3 Hemophilia Gene Therapy Market by Application
  7. 1.3.1 Global Hemophilia Gene Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hemophilia A Gene Therapy
  9. 1.3.3 Hemophilia B Gene Therapy
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Hemophilia Gene Therapy Market Dynamics
  1. 2.1 Hemophilia Gene Therapy Industry Trends
  2. 2.2 Hemophilia Gene Therapy Industry Drivers
  3. 2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Hemophilia Gene Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hemophilia Gene Therapy Market Perspective (2021-2032)
  2. 3.2 Global Hemophilia Gene Therapy Growth Trends by Region
  3. 3.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemophilia Gene Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Hemophilia Gene Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hemophilia Gene Therapy Revenue by Players
  2. 4.1.1 Global Hemophilia Gene Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hemophilia Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemophilia Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hemophilia Gene Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Hemophilia Gene Therapy Players, Product Type & Application
  8. 4.5 Global Hemophilia Gene Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
  11. 4.6.3 2025 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier 3
5 Hemophilia Gene Therapy Market Size by Type
  1. 5.1 Global Hemophilia Gene Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Hemophilia Gene Therapy Revenue Market Share by Type (2021-2032)
6 Hemophilia Gene Therapy Market Size by Application
  1. 6.1 Global Hemophilia Gene Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hemophilia Gene Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Hemophilia Gene Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Spark Therapeutics
  2. 7.1.1 Spark Therapeutics Company Information
  3. 7.1.2 Spark Therapeutics Business Overview
  4. 7.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
  6. 7.1.5 Spark Therapeutics Recent Developments
  7. 7.2 Ultragenyx
  8. 7.2.1 Ultragenyx Company Information
  9. 7.2.2 Ultragenyx Business Overview
  10. 7.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
  12. 7.2.5 Ultragenyx Recent Developments
  13. 7.3 Shire PLC
  14. 7.3.1 Shire PLC Company Information
  15. 7.3.2 Shire PLC Business Overview
  16. 7.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
  18. 7.3.5 Shire PLC Recent Developments
  19. 7.4 Sangamo Therapeutics
  20. 7.4.1 Sangamo Therapeutics Company Information
  21. 7.4.2 Sangamo Therapeutics Business Overview
  22. 7.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
  24. 7.4.5 Sangamo Therapeutics Recent Developments
  25. 7.5 Bioverativ
  26. 7.5.1 Bioverativ Company Information
  27. 7.5.2 Bioverativ Business Overview
  28. 7.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
  30. 7.5.5 Bioverativ Recent Developments
  31. 7.6 BioMarin
  32. 7.6.1 BioMarin Company Information
  33. 7.6.2 BioMarin Business Overview
  34. 7.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
  36. 7.6.5 BioMarin Recent Developments
  37. 7.7 uniQure
  38. 7.7.1 uniQure Company Information
  39. 7.7.2 uniQure Business Overview
  40. 7.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
  42. 7.7.5 uniQure Recent Developments
  43. 7.8 Freeline Therapeutics
  44. 7.8.1 Freeline Therapeutics Company Information
  45. 7.8.2 Freeline Therapeutics Business Overview
  46. 7.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
  48. 7.8.5 Freeline Therapeutics Recent Developments
8 North America
  1. 8.1 North America Hemophilia Gene Therapy Revenue (2021-2032)
  2. 8.2 North America Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Hemophilia Gene Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Hemophilia Gene Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Hemophilia Gene Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Hemophilia Gene Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Hemophilia Gene Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Hemophilia Gene Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Hemophilia Gene Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Hemophilia Gene Therapy Revenue by Country
  11. 8.6.1 North America Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hemophilia Gene Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Hemophilia Gene Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hemophilia Gene Therapy Revenue (2021-2032)
  2. 9.2 Europe Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hemophilia Gene Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hemophilia Gene Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Hemophilia Gene Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hemophilia Gene Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hemophilia Gene Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hemophilia Gene Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Hemophilia Gene Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hemophilia Gene Therapy Revenue by Country
  11. 9.6.1 Europe Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hemophilia Gene Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hemophilia Gene Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hemophilia Gene Therapy Revenue (2021-2032)
  2. 10.2 China Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Hemophilia Gene Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Hemophilia Gene Therapy Revenue by Type (2027-2032)
  5. 10.3 China Hemophilia Gene Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Hemophilia Gene Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Hemophilia Gene Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Hemophilia Gene Therapy Revenue by Application (2027-2032)
  9. 10.5 China Hemophilia Gene Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemophilia Gene Therapy Revenue (2021-2032)
  2. 11.2 Asia Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hemophilia Gene Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hemophilia Gene Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Hemophilia Gene Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hemophilia Gene Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hemophilia Gene Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hemophilia Gene Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Hemophilia Gene Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hemophilia Gene Therapy Revenue by Country
  11. 11.6.1 Asia Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hemophilia Gene Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hemophilia Gene Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemophilia Gene Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Hemophilia Gene Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hemophilia Gene Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hemophilia Gene Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hemophilia Gene Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hemophilia Gene Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hemophilia Gene Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hemophilia Gene Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hemophilia Gene Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hemophilia Gene Therapy Revenue by Country
  11. 12.6.1 SAMEA Hemophilia Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hemophilia Gene Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hemophilia Gene Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst